Partner Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.partnertx.com
Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation
- Conditions
- Drug KineticsDrug Effects on Physiology
- Interventions
- Biological: sargramostim
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Partner Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05366283
- Locations
- 🇨🇦
AltaSciences, Mount-Royal, Quebec, Canada
Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors
- Conditions
- Solid Tumor, AdultSolid Tumor
- Interventions
- Biological: SargramostimBiological: Ipilimumab-containing therapy
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Partner Therapeutics, Inc.
- Registration Number
- NCT05284214
- Locations
- 🇺🇸
Partner Therapeutics - No Currently Active Sites, Lexington, Massachusetts, United States
Sargramostim Use in COVID-19 to Recover Patient Health
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Partner Therapeutics, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT04707664
- Locations
- 🇺🇸
Dorrington Medical Associates, Houston, Texas, United States
🇺🇸Synergy Healthcare, Bradenton, Florida, United States
🇺🇸Hometown Urgent Care and Research, Columbus, Ohio, United States
Study of Sargramostim in Patients With COVID-19
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Partner Therapeutics, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT04411680
- Locations
- 🇺🇸
Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States
🇺🇸University of Utah Health, Salt Lake City, Utah, United States
🇺🇸St. Jude Medical Center, Fullerton, California, United States
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
- Conditions
- NSCLC Harboring NRG1 FusionPancreatic Cancer Harboring NRG1 FusionNRG1 FusionSolid Tumours Harboring NRG1 Fusion
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Partner Therapeutics, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT02912949
- Locations
- 🇺🇸
Georgetown University, District of columbia, District of Columbia, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸The Oncology Institute of Hope and Innovation, Cerritos, California, United States